{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010604","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.541544+00:00","generated_at":"2026-06-17T10:46:10.396284+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcellx reports 2022 results; announces Kite collaboration for CART-ddBCMA with $325M upfront","bullets":["Strategic collaboration with Kite (Gilead): $225M upfront + $100M equity; co-commercialize in US, royalties ex-US.","Phase 1 expansion data: 100% ORR, 71% CR/sCR in evaluable rrMM patients; no delayed neurotoxicity.","Pivotal iMMagine-1 trial dosed; Phase 1 ACLX-002 for AML/MDS initiated.","Cash $254.8M at Dec 31, 2022; plus $325M from Kite/Gilead in Jan 2023; expected to fund through BLA filing H1 2025.","Net loss $188.7M for FY2022 vs $65.0M in 2021; R&D expenses $149.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010604","json":"https://secwatch.observer/filing/0000950170-23-010604.json","markdown":"https://secwatch.observer/filing/0000950170-23-010604.md","text":"https://secwatch.observer/filing/0000950170-23-010604.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/0000950170-23-010604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/aclx-20230329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T10:46:10.396284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba9779c9f7d750e9fc7dd12dba5207f18b9b7b0f","claim":"Arcellx, Inc. reported fourth quarter and year ended December 31, 2022 results: net income Net loss was $39.0 million and $20.7 million for the quarters ended December 31, 2022, and 2021, respectively; and $188..","evidence_excerpt":"Arcellx, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/0000950170-23-010604-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $39.0 million and $20.7 million for the quarters ended December 31, 2022, and 2021, respectively; and $188."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}